Product Description
We are developing a novel therapeutic called OPT-302, a VEGF-C/D trap, to be used in combination with existing standard of care anti-VEGF-A therapies.
Mechanisms of Action: VEGF Inhibitor
Novel Mechanism: No
Modality: Fusion Protein
Route of Administration: Injection
FDA Designation: Fast Track - Macular Degeneration|Wet Macular Degeneration *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Opthea
Company Location: SOUTH YARRA, VICTORIA C3 3141
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Brazil, Bulgaria, Canada, Colombia, Croatia, Czech Republic, Denmark, Estonia, France, Germany, Greece, Hungary, India, Israel, Italy, Korea, Latvia, Lithuania, Malaysia, Netherlands, Philippines, Poland, Puerto Rico, Slovakia, Spain, Taiwan, Thailand, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: Neovascular age-related macular degeneration|Wet Macular Degeneration
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| OPT-302-1004 | P3 |
Not yet recruiting |
Neovascular age-related macular degeneration|Wet Macular Degeneration |
2026-05-31 |
|
| OPT-302-1005 | P3 |
Not yet recruiting |
Wet Macular Degeneration|Neovascular age-related macular degeneration |
2026-01-20 |
|
| COAST | P3 |
Active, not recruiting |
Wet Macular Degeneration|Neovascular age-related macular degeneration |
2025-07-01 |
42% |
| ShORe | P3 |
Active, not recruiting |
Wet Macular Degeneration|Neovascular age-related macular degeneration |
2025-07-01 |